In regards to the biotech sector, the author of today’s article advises that “it makes sense to keep an eye on this general area of the market as it is likely to play an increasingly significant role not just in the fight against Covid-19 but also in the war on cancer, the battle against rare diseases, and increasingly on more…
While the Trump administration has not publicly identified the drugmakers and biotechs involved in Operation Warp Speed – its effort to have 300 million doses of a safe and effective COVID-19 vaccine ready by January 2021 – some tiny biotechs have been touting their involvement in the program, sending their stocks soaring. For more, CLICK HERE.
Clinical trial data or regulatory verdicts can send shares of biotech companies skyrocketing – or plummeting. The question then, as the author of today’s article observes, is “how are investors supposed to determine which biotech stocks are capable of outperforming the rest?” One approach is to track analyst sentiment – and the author highlights three biotech stocks that not only…
Today’s article highlights two “compelling small-cap stocks that combine a low cost of entry with the Street’s backing.” More specifically, these two stocks – a biotech firm and a pharmaceutical company – are currently trading for less than $8 a share, have earned “Strong Buy” consensus analyst ratings, and boast significant upside potential. For more, CLICK HERE.
As the end of the second quarter of 2020 approaches, a number of biopharmaceutical companies have data readouts due – and positive trial data could serve as catalysts for those companies’ stocks. For seven biopharmaceutical companies with impending data readouts – and details on their respective potential catalysts – CLICK HERE.
“Biotech penny stocks have always been a big focus for investors but this year has been one of the most active years for the sector,” observes the author of today’s article. And while the coronavirus outbreak has been a major reason for this increased activity, the author notes that “you also have companies hitting big milestones for other health indications.”…
When it comes to investors piling into small-cap companies that are developing potential treatments or vaccines for COVID-19 – and causing shares of those companies to take off – Europe is no different than the U.S., with some small-cap biotech names in Europe having seen four-fold gains. Today’s article looks at a number of those companies – and whether investors…
“The tech sector is once again outperforming the overall market in 2020 as investors continue to go all-in on growth,” observes the author of today’s article. However, the tech giants that have led the market’s rise may have limited upside left in the near term, and tech investors may be better off focusing on small-cap tech stocks. For seven high-quality…
Based on the premise that tech is poised to continue to drive the market for years to come, today’s article highlights three cheap (trading under $10 a share) stocks from the broader technology space to consider due to their growth prospects regardless of renewed market volatility. For more on these three tech stocks, CLICK HERE.
Shares of the small-cap biotech stock highlighted in today’s article have settled back down after surging more than 70% earlier this month in reaction to interim results for the company’s only drug candidate to reach the clinical trial phase. Does that make now a good time to buy? For more on this “flaming hot” biotech firm that could “become a…